Talzenna generics — when can they launch?
Talzenna (Talazoparib Tosylate) · Pfizer Inc. · 70 active US patents · 0 expired
Where Talzenna sits in the generic timeline
Imminent generic cliff: earliest active US patent for Talzenna expires in 2029 (~3 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Composition of Matter — 48 patents
- Method of Use — 22 patents
FDA U-codes carved out by Talzenna patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-3651 | (no description) |
U-2437 | (no description) |
Sample patent estate
Showing 6 of 70 active US patents. View full estate on the Talzenna drug page →
-
This patent protects pharmaceutical compositions that inhibit poly(ADP-ribose)polymerase activity and their use in treating diseases, disorders, and conditions.USPTO title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
-
This patent protects pharmaceutical compositions that inhibit poly(ADP-ribose)polymerase activity and their use in treating diseases, disorders, and conditions.USPTO title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
-
This patent protects a compound with the structure set forth in Formula (I) and Formula (II), which inhibits poly(ADP-ribose)polymerase activity.USPTO title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
-
This patent protects a compound with a specific structure, which is an inhibitor of poly(ADP-ribose)polymerase (PARP) activity.USPTO title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
-
This patent protects a compound with a specific structure, which is an inhibitor of poly(ADP-ribose)polymerase (PARP) activity.USPTO title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
-
This patent protects pharmaceutical compositions that inhibit poly(ADP-ribose)polymerase activity and their use in treating diseases, disorders, and conditions.USPTO title: Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Sources
- FDA Orange Book — patents listed against Talzenna (NDA)
- Talzenna drug profile — full patent estate, indications, clinical trials, pricing
- Pfizer Inc. patent portfolio
- Patent cliff 2029 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Talzenna — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →